Advertisement
Organisation › Details
Immatics N.V. (Nasdaq: IMTX)
Start | 2020-03-17 planned | |
Group | Immatics (Group) | |
Industry | cancer drug | |
Industry 2 | ACTengine® cell therapy product | |
Person | Singh, Harpreet (Immatics 201907– CEO before CSO + CEO of Immatics US + Co-Founder) | |
Person 2 | Christ, Arnd (Immatics 202010– CFO before InflaRx + Proteros + MediGene + NovImmune + Probiodrug + Hoechst) | |
Region | Netherlands_oo | |
Country | Netherlands | |
City | n. a. | |
Address record changed: 2020-03-19 | ||
Basic data | Employees | E: 501 to 1,000 (2023-12-31) |
Currency | EUR | |
Annual sales | 53,997,000 (revenue, consolidated (2023) 2023-12-31) | |
Profit | -96,994,000 (2023-12-31) | |
Cash | 425,895,000 (2023-12-31) | |
Record changed: 2024-10-10 |
Advertisement
More documents for Immatics (Group)
- [1] Immatics N.V.. (10/10/24). "Press Release: Immatics Announces Proposed $150 Million Public Offering". Houston, TX & Tübingen....
- [2] Immatics N.V.. (10/10/24). "Press Release: Immatics Announces Updated Phase 1b Clinical Data on ACTengine IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial". Houston, TX & Tübingen....
- [3] Immatics N.V.. (7/31/24). "Press Release: Immatics Appoints Alise Reicin to Board of Directors". Houston, TX & Tübingen....
- [4] Immatics N.V.. (10/24/23). "Press Release: Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy". Houston, TX & Tübingen....
- [5] Immatics N.V.. (9/11/23). "Press Release: Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics". Cambridge, MA & Tübingen....
- [6] Immatics N.V.. (7/24/23). "Press Release: Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb". Tübingen & Houston, TX....
- [7] MicrofluidX Ltd.. (5/2/23). "Press Release: MicrofluidX and Immatics Working Together on Automated End-to-End Bioprocessing for TCR-T Therapies". Stevenage & Houston, TX....
- [8] Immatics N.V.. (5/2/23). "Press Release: Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine IMA203 TCR-T Targeting PRAME". Houston, TX & Tübingen....
- [9] Immatics N.V.. (5/1/23). "Press Release: Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration". Tübingen & Houston, TX....
- [10] Immatics N.V.. (10/10/22). "Press Release: Immatics Announces $110 Million Underwritten Offering of Ordinary Shares". Houston, TX & Tübingen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top